Acadia Pharma (ACAD) NUPLAZID NDA Accepted for Review; 05/01/16 PDUFA Date Set

Go back to Acadia Pharma (ACAD) NUPLAZID NDA Accepted for Review; 05/01/16 PDUFA Date Set

ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis

November 2, 2015 8:03 AM EST

PDUFA Date Set for May 1, 2016

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that the New Drug Application (NDA) for NUPLAZID (pimavanserin) has been accepted for review by the U.S. Food and Drug Administration (FDA) and the agency has granted it Priority Review. ACADIA is seeking FDA approval of NUPLAZID for the treatment of psychosis associated with Parkinsons disease. The FDA granted NUPLAZID Breakthrough... More